Heath Lukatch

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The companys dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy

Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.

Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life. By leveraging clinically validated Immunoglobulin E (IgE) biology with novel ECRI pharmacology, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling—IgE bound to the effector cell. The company was founded by leaders in the field of IgE biology and the molecular pharmacology of anti-IgE therapeutics.

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Magnus Medical is a privately held medical device company driven to transform lives by restoring mental health. The company is a developer of brain stimulation technology for the treatment of neuropsychiatric disorders. Its first product is the SAINT™ Neuromodulation System, granted Breakthrough Device Designation and 510(k) clearance by the U.S. Food & Drug Administration (FDA) in September 2022 for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte’s Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte’s PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease and VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Welcome to Halo Neuroscience's home on LinkedIn. Please follow us to learn more about how the brain impacts human performance. Below you can read more information about our company. You can also send us an email at hello@haloneuro.com, or see our available job postings at haloneuro.com/careers. ––––––– Halo Neuroscience is a neurotechnology company focused on human performance. Our first product, Halo Sport, utilizes neuropriming technology to accelerate the neurologic gains of strength and skill learning that result from athletic training. Since coming out of stealth in February 2016, the reception has been strong. Halo Sport is now live with teams and athletes from the NBA, MLB, NFL, Olympics, and U.S. Military. The company has been covered in hundreds of publications, including a feature in Sports Illustrated that details Halo's work with NFL prospects training for the Draft. In March 2016, Halo won the MIT Sloan Sports conference startup competition, and Halo Sport has over 28 filed patents. Halo has raised $9M in series A funding from top-tier venture investors like Andreessen Horowitz, Lux Capital, SoftTech VC, and JAZZ Partners. Our founders are neurotechnology veterans — Dr. Daniel Chao, Halo co-founder and CEO, received his MD and MS in neuroscience from Stanford. Dr. Brett Wingeier, Halo co-founder and CTO, earned his biomedical engineering doctorate with studies at Tulane, Stanford, and Swinburne, and is also a U.S. Registered Patent Agent named on 25 U.S. patents.

SI-BONE® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (SI) joint. SI-BONE developed an innovative, patented implant to fuse the SI joint. The iFuse Implant System® provides a less invasive alternative to traditional sacroiliac (SI) joint fusion surgery and has been used in over 65,000 procedures to date. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com/risks. We are aware of active recruitment scams using the SI-BONE name, in which individuals pose as our recruiters and post fake remote job openings and make fake job offers on the Internet. Please note, we will never make an offer of employment without conducting multiple rounds of interviews face-to-face using secure video-conferencing technology. We will never ask candidates to cash checks or make a payment in order to be considered for a position. SI-BONE only uses company email addresses, which contain “@si-bone.com” to communicate with candidates. If you believe you’ve been a victim of a phishing scam, please visit the Cybersecurity & Infrastructure Security Agency at https://www.cisa.gov/be-cyber-smart/report-incident learn how to report it.

Flexion Therapeutics (NASDAQ: FLXN) is a biopharmaceutical company focused on the discovery, development & commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions. Flexion is based in Burlington, Massachusetts. View our terms of use: https://flexiontherapeutics.com/terms-of-use/

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The companys dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy

Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.

Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life. By leveraging clinically validated Immunoglobulin E (IgE) biology with novel ECRI pharmacology, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling—IgE bound to the effector cell. The company was founded by leaders in the field of IgE biology and the molecular pharmacology of anti-IgE therapeutics.